-
Trichomoniasis is the most common curable sexually transmitted infection (STI) in young, sexually active women, according to the Centers for Disease Control and Prevention. An estimated 7.4 million new cases occur each year in U.S. women and men.
-
Four hundred thousand (1.6% of U.S. adolescents) experience serious physical and/or sexual dating violence each year.
-
Since results of the 2002 Women's Health Initiative (WHI) report suggested that use of menopausal hormone therapy increases risk of coronary heart disease, science has examined the timing of therapy initiation on safe use of such treatment.
-
Is your facility participating in National HIV Testing Day on June 27? If not, you may be missing an important community outreach opportunity to help people learn their HIV status.
-
The investigators prospectively enrolled and followed a cohort of 97 teens before and six, 12, and 18 months after starting DMPA.
-
In a multinational observational study, independent from pharmaceutical support and involving both academic and community treatment centers, long-term follow-up for chronic myelogenous leukemia (CML) patients who, after two years of imatinib therapy, were in complete cytogenetic remission was undertaken for a median of 5.8 years. Although side effects were common, only a very small percentage of patients discontinued the drug and the majority maintained their cytogenetic response. In fact, the incidence of second malignancies and overall survival were no different for the CML patients in this cohort than for the general population in Italy.
-
Limited data are available to guide the decision between up-front allogeneic hematopoietic cell transplantation (HCT) or imatinib on long-term outcomes for accelerated phase chronic myelogenous leukemia (CML).
-
A 71-year-old retired police officer was admitted through the emergency room with right upper quadrant pain and low-grade fever.
-
-
Anticholinergic drugs for COPD; pioglitazone for diabetes prevention; insulin degludec in Phase 3 trials; and FDA Actions.
